Position in EXEL
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$2,809,841
+$994,265 QoQ
Shares Held
51,642
+22.0% QoQ
Ownership
0.021%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#232
of 751 holders
Holding Since
Sep 2023
9 quarters on record
Voting authority
Sole 8%
Shared 0%
None 92%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NewEdge Wealth, LLC holds $28,019,722 across 22 Biotechnology names. EXEL ranks #4 (10.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
11,305 | $5,615,532 | |
| 2 | BHVN |
Biohaven Ltd.
|
245,670 | $3,655,569 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
34,890 | $3,033,685 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
51,642 | $2,809,841 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,094 | $2,737,566 | |
| 6 | INVA |
Innoviva, Inc.
|
99,367 | $2,256,624 | |
| 7 | NVAX |
Novavax Inc
|
100,559 | $947,265 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
22,562 | $880,143 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,809,841 | 51,642 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $1,815,576 | 42,331 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,239,293 | 28,275 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $1,050,630 | 25,439 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $912,191 | 20,694 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $427,459 | 11,578 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $346,286 | 10,399 | Shares | Sole | 2025-02-05 | |
| 2023-12-31 | $16,339,684 | 681,104 | Shares | Sole | 2024-01-29 | |
| 2023-09-30 | $10,237,839 | 468,551 | Shares | Sole | 2023-11-08 | |
| No filing history on record for this holder in this stock. | ||||||